The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | ADCLEC.SYN1: combinatorial CAR shows preclinical potential for R/R AML
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the rationale for a chimeric antigen receptor (CAR) designed to target both ADGRE2 and CLEC12A in order to enhance anti-leukemic efficacy without increasing toxicity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). ADGRE2 and CLEC12A are both highly co-expressed in AML, but with low levels of overlapping expression in normal cells. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Sascha Haubner, MD, has received research support from Takeda Pharmaceutical Company Ltd.
